Results 11 to 20 of about 1,881,376 (382)

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus [PDF]

Cell Reports, 2017
Summary: Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing
Katie A. Howell, Jennifer M. Brannan, Christopher Bryan, Andrew McNeal, Edgar Davidson, Hannah L. Turner, Hong Vu, Sergey Shulenin, Shihua He, Ana Kuehne, Andrew S. Herbert, Xiangguo Qiu, Benjamin J. Doranz, Frederick W. Holtsberg, Andrew B. Ward, John M. Dye, M. Javad Aman   +16 more
doaj   +3 more sources

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

New England Journal of Medicine, 2021
BACKGROUND Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of
Anil K Gupta, Y. Gonzalez-Rojas, Erick Juarez, M. Crespo Casal, J. Moya, D. Falci, E. Sarkis, Joel Solis, Hanzhe Zheng, Nicola E. Scott, A. Cathcart, C. Hebner, J. Sager, E. Mogalian, C. Tipple, A. Peppercorn, Elizabeth L. Alexander, P. Pang, A. Free, C. Brinson, M. Aldinger, A. Shapiro   +21 more
semanticscholar   +1 more source

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition [PDF]

, 2013
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broadly neutralizing antibodies 2F5 and 4E10. To date, no immunization regimen in animals or humans has produced HIV-1 neutralizing MPER-specific antibodies ...
Aasa-Chapman, Marlén M. I., Battella, Simone, Bonvin, Alexandre M. J. J., Davis, David, El Khattabi, Mohamed, Favier, Adrien, Forsman Quigley, Anna, Hinz, Andreas, Hock, Miriam, Hulsik, David Lutje, Langedijk, Johannes P. M., Liu, Ying-ying, Macheboeuf, Pauline, McCoy, Laura E., Poignard, Pascal, Ramos, Alejandra, Rutten, Lucy, Sabin, Charles, Seaman, Michael S., Simorre, Jean-Pierre, Strokappe, Nika M., Verrips, C. Theo, Weiss, Robin A., Weissenhorn, Winfried   +23 more
core   +18 more sources

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

Nature Communications, 2021
Understanding how antibody responses to SARS-CoV-2 evolve during infection may provide important insight into therapeutic approaches and vaccination for COVID-19.
S. Dispinseri, M. Secchi, M. Pirillo, M. Tolazzi, M. Borghi, C. Brigatti, M. D. De Angelis, M. Baratella, E. Bazzigaluppi, G. Venturi, F. Sironi, A. Canitano, I. Marzinotto, C. Tresoldi, F. Ciceri, L. Piemonti, D. Negri, A. Cara, V. Lampasona, G. Scarlatti   +19 more
semanticscholar   +1 more source

Neutralizing antibody titres in SARS-CoV-2 infections

Nature Communications, 2021
The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed.
E. Lau, O. Tsang, D. Hui, M. Kwan, Wai-Hung Chan, S. Chiu, R. Ko, K. Chan, Samuel M. S. Cheng, Ranawaka A.P.M Perera, B. Cowling, L. Poon, M. Peiris   +12 more
semanticscholar   +1 more source

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways

iScience, 2022
Summary: The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and ...
Fangzhu Zhao, Celina Keating, Gabriel Ozorowski, Namir Shaabani, Irene M. Francino-Urdaniz, Shawn Barman, Oliver Limbo, Alison Burns, Panpan Zhou, Michael J. Ricciardi, Jordan Woehl, Quoc Tran, Hannah L. Turner, Linghang Peng, Deli Huang, David Nemazee, Raiees Andrabi, Devin Sok, John R. Teijaro, Timothy A. Whitehead, Andrew B. Ward, Dennis R. Burton, Joseph G. Jardine   +22 more
doaj   +1 more source

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Science Translational Medicine, 2021
LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection. A monoclonal for SARS-CoV-2 Among the most promising therapeutic options for individuals with coronavirus ...
Bryan E. Jones, P. Brown-Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, J. Davies, T. Cujec, C. Wiethoff, J. Blackbourne, B. Heinz, Denisa Foster, R. Higgs, D. Balasubramaniam, Lingshu Wang, Yi Zhang, E. Yang, Roza Bidshahri, Lucas Kraft, Yuri Hwang, Stefanie Žentelis, Kevin R. Jepson, R. Goya, Maia A. Smith, D. W. Collins, Samuel J. Hinshaw, Sean A. Tycho, Davide Pellacani, Ping Xiang, Krithika Muthuraman, S. Sobhanifar, Marissa H. Piper, Franz J. Triana, J. Hendle, A. Pustilnik, A. Adams, Shawn J. Berens, R. Baric, David R. Martinez, R. Cross, T. Geisbert, V. Borisevich, O. Abiona, H. Belli, M. de Vries, Adil Mohamed, Meike Dittmann, M. Samanovic, M. Mulligan, J. Goldsmith, C. Hsieh, N. Johnson, D. Wrapp, J. McLellan, B. Barnhart, B. Graham, J. Mascola, C. Hansen, E. Falconer   +56 more
semanticscholar   +1 more source

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

New England Journal of Medicine, 2020
Background Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, we ...
D. Weinreich, S. Sivapalasingam, Thomas D. Norton, Shazia Ali, Haitao Gao, R. Bhore, B. Musser, Y. Soo, D. Rofail, Joseph Im, C. Perry, C. Pan, R. Hosain, A. Mahmood, John D. Davis, K. Turner, A. Hooper, J. Hamilton, A. Baum, C. Kyratsous, Yunji Kim, A. Cook, W. Kampman, A. Kohli, Yessica Sachdeva, X. Graber, B. Kowal, T. Dicioccio, N. Stahl, L. Lipsich, N. Braunstein, G. Herman, G. Yancopoulos   +32 more
semanticscholar   +1 more source

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

Science Translational Medicine, 2022
The waning efficacy of SARS-CoV-2 vaccines, combined with the continued emergence of variants resistant to vaccine-induced immunity, has reignited debate over the need for booster vaccine doses.
John P. Evans, C. Zeng, Claire Carlin, G. Lozanski, L. Saif, Eugene M. Oltz, R. Gumina, Shan-Lu Liu   +7 more
semanticscholar   +1 more source

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Science, 2022
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled
David J. Leggat, Kristen W. Cohen, Jordan R. Willis, W. Fulp, Allan C. deCamp, O. Kalyuzhniy, C. Cottrell, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Torben Schiffner, Alessia Liguori, Farhad Rahaman, Angela Lombardo, V. Philiponis, Rachael E. Whaley, A. Seese, Joshua Brand, Alexis M Ruppel, W. Hoyland, N. Yates, L. D. Williams, Kelli M. Greene, Hongmei Gao, Celia Mahoney, M. Corcoran, A. Cagigi, Alison Taylor, David M. Brown, D. Ambrozak, Troy Sincomb, Xiaozhen Hu, Ryan D. Tingle, Erik Georgeson, Saman Eskandarzadeh, Nushin B Alavi, Danny Lu, T. Mullen, Michael Kubitz, Bettina Groschel, J. Maenza, O. Kolokythas, N. Khati, J. Bethony, S. Crotty, M. Roederer, G. K. Karlsson Hedestam, G. Tomaras, D. Montefiori, D. Diemert, R. Koup, D. Laufer, M. McElrath, A. McDermott, W. Schief   +56 more
semanticscholar   +1 more source